Abstract:Abstract BACKGROUND AND AIMS Haemodialysis patients are known to be susceptible to a wide range of early and long-term complications such as chronic inflammation, infections, malnutrition, mineral bone disorders (CKD-MBD) and cardiovascular disease that significantly affect the incidence of mortality.The aim of this study is to assess the presence of traditional risk factors for mortality such as diabetes mellitus or cardiovascular disease on one hand and non-traditional risk factors on the other hand (chronic inflammation, CKD-MBD). METHOD We conducted a single-centre study that included 63 CKD G5D patients (haemodialysis for 1–5 years) followed up for 48 months. All patients have been assessed at baseline, regarding cardiovascular disease (medical history, echocardiography and ECG), we performed using standard methods blood biochemistry, complete blood count and markers of inflammation (CRP, IL-6) and markers of CKD-MBD (sKlotho, iPTH, serum calcium and serum phosphorus). RESULTS After 24 months of follow-up, we found a mortality rate of 22.23%, while after 48 months, the mortality rate was of 50.73%. Baseline plasma IL-6 levels showed a strong statistically significant correlation with sKlotho (r = 0.57, P = 0.001), but no statistically significant correlation with other elements of CKD-MBD was present (serum calcium, serum phosphorus and iPTH). sKlotho showed a positive correlation with haemodialysis efficiency (eKTV) (r = 0.26, P = 0.04)., Decreased levels of sKlotho at baseline correlated significantly with the presence of signs of ischaemia on ECG (190.3 versus 381.57 pg/mL; P = 0.028). Inflammation markers (IL-6 and CRP) showed no statistically significant correlation with any of the markers of cardiovascular disease (presence of vascular calcifications and of left ventricular hypertrophy). The level of iPTH at baseline was significantly lower in the group of patients that survived the following 4 years of haemodialysis (428.08 ± 315.39 versus 666.76 ± 484.55 pg/mL, P = 0.029). In a Cox proportion-hazards regression analysis of predicting factors of mortality, only age and not inflammation markers (IL-6 and CRP) showed a statistically significant correlation with 4-year mortality (P = 0.032). Patients with higher levels of sKlotho showed a decreased risk of mortality, however not statistically significant. We found a higher risk of all-cause mortality after 24 months in patients with diabetes mellitus [OR 6.9, 95% confidence interval (95% CI) 1.6924–28.1469; P = 0.007], and after 48 months in patients with a history of cerebro-vascular disease (OR 21.8571, 95% CI 1.2018–397.5026; P = 0.0371) and with left ventricular hypertrophy (OR 2.7259, 95% CI 0.9596–7.7437; P = 0.0598). CONCLUSION In our study, although the inflammation marker IL-6 showed correlations with features of CKD-MBD, it did not lead to an increased mortality, which was influenced rather by traditional risk factors such as age, diabetes mellitus or history of cardiovascular disease, but also by CKD-MBD (iPTH).

Gut dysbiosis and mortality in hemodialysis patients

Dysbiosis of the Intestinal Microbiota in Neurocritically Ill Patients and the Risk for Death.

The Effects of Hemodialysis and Peritoneal Dialysis on the Gut Microbiota of End-Stage Renal Disease Patients, and the Relationship Between Gut Microbiota and Patient Prognoses

Unraveling Intestinal Microbial Shifts in ESRD and Kidney Transplantation: Implications for Disease-Related Dysbiosis

Gut dysbiosis in acute-on-chronic liver failure and its predictive value for mortality.

Association between gut microbial diversity and technique failure in peritoneal dialysis patients

Microbiota analysis in the hemodialysis population - Focusing on Enterobacteriaceae

Gut Microbiota in Patients Receiving Dialysis: A Review

Gut Bacterial Translocation May Aggravate Microinflammation in Hemodialysis Patients

MO933: are Chronic Inflammation and CKD-MBD Risk Factors of Mortality in Hemodialysis Patients?

#1908 Characterization of the gut mycobiome composition in patients with end-stage renal disease

Gut Microbiome and Microbiome-Derived Metabolites in Patients with End-Stage Kidney Disease

The Role of the Gut Microbiota in Complications among Hemodialysis Patients

The Association between Baseline Serum Lipids and Mortality in Peritoneal Dialysis Patients

Clinical Characteristics Associated with the Properties of Gut Microbiota in Peritoneal Dialysis Patients

Altered monocytic phenotypes are linked with systemic inflammation and may be linked to mortality in dialysis patients

Alterations to the Gut Microbiota and Their Correlation With Inflammatory Factors in Chronic Kidney Disease

Dysbiosis of the gut microbiome is associated with CKD5 and correlated with clinical indices of the disease: a case-controlled study

Proportions of Proinflammatory Monocytes Are Important Predictors of Mortality Risk in Hemodialysis Patients

Gut Bacterial Translocation is Associated with Microinflammation in End‐stage Renal Disease Patients

Dysbiosis of the gut microbiota is associated with in-hospital mortality in patients with antibiotic-associated diarrhoea: a metagenomic analysis